Raising the sun: Japan biotech looks to level up

S2S Japanシンポジウム、mRNA標的低分子薬や腫瘍溶解性ペプチドなど日本発シーズを紹介

AN Venture Partners to Host “S2S Japan 2025 Symposium” on November 13

Crystalys Therapeutics Advances Phase 3 Trials of Dotinurad for the Treatment of Gout with Dosing of First Patient

AN Venture Partner’s New Portfolio Company, Crystalys Therapeutics Launches with $205M Series A Financing to Advance Next-Generation Gout Treatment

ベンチャー探訪 Pahr Therapeutics社、肺動脈性肺高血圧症にAHRを制御する治療薬を開発へ

日本発なのに米国企業へ“転生”続々、創薬スタートアップ　「100均問題」足かせ

AN Venture Partners Announces the Addition of Mikael Dolsten as Advisor

国循発ベンチャー、1400万ドルを調達　　パー・セラピューティクス、PAHの治療法開発へ

Pahr Therapeutics raises $14 million seed financing to pursue innovative treatments for Pulmonary Arterial Hypertension

日米に拠点を持つVCの米AN Venture Partners社、第1号ファンドを2億ドルでクローズ

Biotech VC raises $200M to focus on Japan’s ‘untapped source’ of innovation

国内最大の創薬ファンド　米ANV、日本向け300億円調達

AN Venture Partners Announces Final Close of $200M Fund I

AN Venture Partners lines up $200M freshman fund to champion Japanese innovation

AN Venture Partners Promotes Paula Schultheiss to Associate and Names Three New Fellows

遺伝情報、コピペで書き換える分子　解析で難病治療に光

City Therapeutics and Biogen Announce Strategic Research Collaboration to Develop Select Novel RNAi‑based Therapies

Typewriter Therapeutics Hires R&D Japan Head